PSTV

Over the past six months, Plus Therapeutics, Inc.'s stock price has been impacted by several events. The share price declined by 62.91% over the past year. The company received Medicare enrollment approval for its CNSide Diagnostic and secured Blue Shield of California coverage for its CNSide® Cerebrospinal Fluid Assay. Plus Therapeutics initiated manufacturing activities with SpectronRx for REYOBIQ™ and regained compliance with the Nasdaq minimum bid price requirement. The company presented positive interim data for REYOBIQ™ and the U.S. FDA granted Orphan Drug Designation to REYOBIQ™. Shareholder dilution was identified as a new major risk.